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Therapeutic measures in proteinuric nephropathy. The level of
proteinuria is one of the most important risk factors for progres-
sive renal function loss in renal diseases. Any therapeutic mea-
sure that reduces proteinuria will slow or halt the progression of
proteinuric nephropathies. Blockade of the renin-angiotensin-
aldosterone system (RAAS) with angiotensin-converting en-
zyme (ACE) inhibitors or AT1-receptor antagonists (ARA)
is currently the most powerful available antiproteinuric treat-
ment. Recent investigations point out that blockade of RAAS
at other levels (e.g., aldosterone or renin antagonists) could
also induce a significant decrease in proteinuria. Because an-
giotensin II is also generated from angiotensin I by enzymes
other than ACE, ARA would provide a more effective block-
ade of angiotensin II; however, ACE inhibition increases plasma
levels of substances such as bradykinin and N-acetyl-seryl-
aspartyl-lysyl-proline, which have strong antifibrotic proper-
ties. These differential effects of ACE inhibitors and ARA
are the rationale for combined administration of both agents,
which in clinical studies has demonstrated a significantly higher
antiproteinuric and renoprotective effect than by either drug
alone. Salt and protein restriction, as well as cautious use of
diuretics, can also increase the antiproteinuric effect of RAAS
blockade. Treatment with statins or other lipid-lowering agents
leads to reduction in proteinuria levels, as some meta-analyses
have demonstrated. Smoking is associated with an increased
risk for the appearance of proteinuria, so cessation of smok-
ing should be mandatory in proteinuric renal diseases. Recent
studies have highlighted an epidemic increase of obesity-related
proteinuric glomerulopathies; weight loss is effective not only in
this condition, but also in overweight patients with proteinuric
nephropathies of other etiologies.
In the past decade, an important number of clinical
studies have clearly established that the level of protein-
uria or albuminuria is one of the most important risk fac-
tors for progressive renal function loss in both diabetic
and nondiabetic renal diseases [1–4]. Any therapeutic
measure that reduces the level of proteinuria will slow
or halt the rate of renal function loss and, conversely,
those individual patients in whom proteinuria does not
decrease after the introduction of well-known beneficial
therapies, such as angiotensin-converting enzyme (ACE)
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inhibitors, will not obtain the expected benefits of these
therapies [5]. The main reason for this relationship be-
tween proteinuria and renal failure progression relies on
the tubulointerstitial damage induced by proteinuria.
Many experimental studies have demonstrated that
proteins abnormally filtered by the glomerulus in the
setting of diabetic nephropathy or other renal diseases
are actively reabsorbed by proximal tubular cells through
a receptor-mediated endocytosis, and degraded by lyso-
somes [6]. Proximal tubular cells show an intense prolifer-
ation when protein concentration increases in the tubular
lumen, and synthesize a large number of vasoactive
and proinflammatory substances including angiotensin,
endothelin-1, transforming growth factor beta, RANTES
(regulated upon activation normal T-cell expressed and
secreted) monocyte chemoattractant protein-1, and os-
teopontin [7, 8]. These substances activate the migration
of macrophages and T lymphocytes into the renal inter-
stitium; the presence of cellular infiltrates is a classical
observation in renal biopsies of patients with proteinuric
renal diseases. These interstitial infiltrates, in turn, are
a continuous source of proinflammatory and profibrotic
factors that gradually transform the infiltrative appear-
ance of interstitium into a diffuse and irreversible fibrosis.
Because of the initial histological descriptions of many
glomerular diseases, it is well known that the severity
of tubulointerstitial changes portends a more ominous
prognosis than the glomerular lesions [9]: the level of
glomerular proteinuria, continuously inducing the tubu-
lointerstitial damage summarized above, appears to be
the most important pathogenic link between glomerular
disorders and tubulointerstitial fibrosis.
The role of those specific receptors and transcription
factors that promote the proliferation of tubular cells
and upregulate the synthesis of proinflammatory and
profibrotic mediators has been partially clarified in re-
cent years [6–8, 10, 11]. Nuclear transcription factor jB
appears to play a fundamental pathogenic role. Thus, in
experimental models of nephrotic syndrome (adriamy-
cin-induced nephrosis), treatment with an antioxidant
drug (pyrrolidine dithiocarbamate), which specifically
blocks nuclear transcription factor jB, prevented the de-
velopment of tubulointerstitial damage in spite of the per-
sistence of massive proteinuria [12].
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In this review, we summarize those antiproteinuric
therapeutic measures that have consistently demon-
strated their efficacy in the clinical practice, as well as
those therapeutic agents that have shown promising ben-
eficial effects in experimental studies and preliminary
clinical investigations.
BLOCKADE OF THE RENIN-ANGIOTENSIN-
ALDOSTERONE SYSTEM WITH ACE
INHIBITORS OR AT1-RECEPTOR ANTAGONISTS
Blockade of the renin-angiotensin-aldosterone system
(RAAS) by ACE inhibitors or AT1-receptor antagonists
(ARA) remains the most powerful antiproteinuric treat-
ment currently available. Shortly after their introduc-
tion as antihypertensive drugs, ACE inhibitors showed
a striking antiproteinuric efficacy, which was largely in-
dependent of their blood pressure–lowering effect [13].
Confirming preliminary observations [5], large, prospec-
tive, multicenter studies demonstrated that these drugs
significantly reduce the risk for renal function loss in di-
abetic and nondiabetic nephropathies [14–17]. The sub-
sequent introduction of ARA showed that these agents
share the antiproteinuric properties of ACE inhibitors
[18]. Recent landmark studies have demonstrated a reno-
protective effect of losartan and irbesartan in patients
with type 2 diabetic nephropathy [19–21], which signif-
icantly reduces the risk of end-stage renal failure and
progression from microalbuminuria to overt nephropa-
thy. More recently, trandolapril, an ACE inhibitor, has
demonstrated its effectiveness to reduce the risk for pro-
gression from normoalbuminuria to microalbuminuria
in hypertensive type 2 diabetic patients, thus affording
primary prevention for diabetic nephropathy with ACE
inhibition [22].
A detailed description of all large studies that have
firmly established the antiproteinuric and renoprotective
effects of ACE inhibitors and ARA in proteinuric dia-
betic and nondiabetic nephropathies is beyond the scope
of this review, but the following remarks, shared by all
these studies, are worth underlining, given their impor-
tance for clinical practice. (1) The renoprotection induced
by these drugs is closely related to their antiproteinuric
effect. (2) The reduction in proteinuria induced by ACE
inhibitors and ARA is already observed in the first weeks
of treatment. (3) Their antiproteinuric effect is largely in-
dependent of their blood pressure–lowering action. (4)
Reduction in proteinuria is a dose-dependent effect of
both ACE inhibitors and ARA. (5) The antiproteinuric
and renoprotective properties of these drugs appear to be
shared by all ACE inhibitors and ARA so far tested. (6)
Although there are very few comparative studies [23],
the antiproteinuric and renoprotective efficacy of ACE
inhibitors and ARA appear to be similar.
These common properties indicate that, when an ACE
inhibitor or an ARA is prescribed for patients with
proteinuric nephropathies, the level of proteinuria or al-
buminuria is the most appropriate marker of their ther-
apeutic effectiveness. In the case of poor reductions in
proteinuria, the dose of the selected agent should be pro-
gressively increased; if proteinuria remains unacceptably
high after reaching the highest therapeutic doses, clinical
factors that can reduce the antiproteinuric properties of
ACE inhibitors and ARA (see later in this article) should
be investigated and treated. The following step, accord-
ing to recent studies, should probably be the combined
blockade of RAAS at different levels (see later in this
article).
Another fundamental concept, raised by several land-
mark studies in recent years, consists of the significant de-
crease of cardiovascular events among high-risk patients
(diabetic patients, patients with ischemic heart disease or
peripheral vascular disease) treated with ACE inhibitors
[24]. Considering that recent investigations have clearly
concluded that the presence of renal insufficiency is a
significant risk factor for the development of cardiovas-
cular events [25], the cardiovascular protection given by
RAAS blockade is of paramount importance for patients
receiving these drugs in the setting of proteinuric renal
diseases.
OTHER RAAS BLOCKADE: ALDOSTERONE
AND RENIN ANTAGONISTS
Several experimental studies have shown that aldos-
terone, the final step in the process of RAAS activa-
tion, is a potent inducer of endothelial dysfunction and
stimulates inflammation and fibrosis in the renal and
cardiac interstitium. Aldosterone antagonists counteract
renal damage in several experimental models of renal
disease, and spironolactone has demonstrated a signif-
icant beneficial effect in patients with congestive heart
failure already treated with ACE inhibitors [26]. Some
clinical studies have shown that spironolactone reduces
proteinuria in diabetic and nondiabetic nephropathies,
and in a recent comparative study, reduction in protein-
uria by spironolactone was higher than the reduction by
enalapril [27]. Similar preliminary results have been ob-
tained with eplerenone, another aldosterone antagonist,
which induces an important reduction in microalbumin-
uria in diabetic patients [28].
The possibility to block RAAS at its initial steps has
emerged with a renewed interest after the synthesis of
renin inhibitors available for oral administration [29]. Al-
though these drugs offer a powerful antihypertensive effi-
cacy, future research must address whether they share the
antiproteinuric and renoprotective properties of other
RAAS blockers.
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COMBINED RAAS BLOCKADE
The possibility that combined RAAS blockade, mainly
through the simultaneous administration of an ACE in-
hibitor and an ARA, would offer a stronger antiprotein-
uric and renoprotective effect than either drug alone was
first suggested by experimental studies and clinical trials
involving a small number of patients. However, the grow-
ing number of these studies, almost all confirming the su-
periority of combined therapy, prompted the design and
performance of large trials. One of them enrolled 263
patients with nondiabetic renal diseases. These patients
were randomly assigned to treatment with losartan, tran-
dolapril, or a combination of both drugs at half doses. Re-
duction in proteinuria was significantly higher in patients
receiving the combination therapy, and the number of pa-
tients in this group who reached the primary end point
(doubling of serum creatinine or end-stage renal disease)
was significantly lower than in the other two groups: 11%
versus 23% and 23%. No differences in blood pressure
that could have influenced these striking results were ob-
served between the groups [30]. Other clinical studies
have shown that combination therapy with an ACE in-
hibitor and ARA also offers increased proteinuria reduc-
tion in diabetic nephropathy [31], and large multicenter
studies are currently in progress to confirm these findings
and answer the crucial question of a possible better reno-
protection afforded by combination ACE inhibitors and
ARA in diabetic patients.
From a theoretical point of view, there are several
physiologic reasons to explain the superiority of com-
bined ACE inhibition and ARA therapy over either drug
alone [32]. ACE inhibitors block the conversion of an-
giotensin I to angiotensin II, but ACE inhibition alone
does not provide a complete blockade of the RAAS.
Angiotensin II can be generated from angiotensin I by
enzymes other than ACE, such as chymase and other ser-
ine proteases. Some studies have estimated that almost
40% of angiotensin I is converted to angiotensin II by en-
zymes other than ACE, particularly in pathological con-
ditions. Considering these ACE-independent pathways
of angiotensin II generation, ARA should be more ef-
fective than ACE to counteract the deleterious effects
of angiotensin II, directly inhibiting the binding of an-
giotensin II to AT1 receptors. In addition, ARA can lead
to an augmented stimulation of AT2 receptors that in-
duce vasodilatation and decrease cellular proliferation.
Nevertheless, ACE inhibition has several specific benefi-
cial effects not shared by ARA. It increases the plasma
levels of bradykinin and other substances catabolized by
ACE, such as N-acetyl-seryl-aspartyl-lysyl-proline, which
possesses strong antifibrotic properties [33].
The complex structure of the RAAS offers the possi-
bility of combined blockade at other levels. Thus, some
investigators have shown that the combination of an ACE
inhibitor and an aldosterone antagonist offers a stronger
antiproteinuric effect than either drug alone [27]. How-
ever, in contrast with the remarkable high tolerance to
the combination ACE inhibitor and ARA [30], the com-
bined use of ACE inhibitors and aldosterone antagonist
carries a very serious risk of hyperkalemia [27, 34].
THERAPEUTIC MEASURES THAT ENHANCE
THE ANTIPROTEINURIC AND
RENOPROTECTIVE EFFECT OF RAAS
BLOCKADE
Since publication of the results of the Modification of
Diet in Renal Disease study [35], it is generally agreed
that blood pressure control should be targeted to values
lower than 130/80 mm Hg in patients with proteinuric re-
nal diseases. For the reasons summarized above, the basis
of antihypertensive treatment should consist of drugs that
block the RAAS. However, many patients will need the
addition of more antihypertensive drugs, which should be
selected according to individual patient characteristics.
It is generally agreed that antihypertensive drugs other
than ACE inhibitors and ARA do not posses specific an-
tiproteinuric properties, but lowering of blood pressure
by itself decreases proteinuria in a nonspecific manner.
Some authors have suggested that nondihydropyridine
calcium-channel blockers could have a specific antipro-
teinuric effect, mainly in patients with hypertension
associated with type 2 diabetes [36]. However, other stud-
ies have contradicted these results [37]. Another thera-
peutic measure that would enhance the antiproteinuric
properties of RAAS blockade is protein restriction [38],
although this measure is usually restricted to patients
with moderate-to-severe degrees of chronic renal insuffi-
ciency. The Modification of Diet in Renal Disease study
also demonstrated the antiproteinuric effect of protein
restriction [35]. Salt restriction and diuretics could also
potentiate the reduction in proteinuria induced by ACE
inhibitors and ARA [39].
TREATMENT OF HYPERLIPIDEMIA
Despite the compelling experimental studies that have
shown an important role of hyperlipidemia in the pro-
gression of renal diseases, most clinical studies failed to
demonstrate a significant antiproteinuric effect of statins
or other lipid-lowering agents. However, a meta-analysis
of previously published trials concluded that treatment
of hyperlipidemia induces a significant reduction in pro-
teinuria and slows the progression of renal diseases in
comparison with nontreated patients [40]. A recent study
has shown that treatment with atorvastatin in addition
to a regimen of ACE inhibitors or ARA may reduce
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proteinuria and the rate of progression of kidney disease
in patients with hypercholesterolemia [41].
SMOKING
Given the obvious ethical implications precluding the
performance of prospective, controlled studies, retro-
spective data are of enormous importance, because they
show that smoking causes devastating effects in patients
with chronic proteinuric renal diseases [42]. Epidemio-
logic studies have shown that smoking is a significant risk
factor for the detection of proteinuria and microalbumin-
uria in otherwise healthy people [43].
WEIGHT LOSS: IMPROVEMENT OF INSULIN
SENSITIVITY
Obesity is a recognized cause of proteinuria and focal
glomerulosclerosis [44], and recent studies have shown
a worrying growth of obesity-related glomerulopathies,
in parallel with the global epidemic of obesity affect-
ing modern societies [45]. Our group showed that both
weight loss induced by low-calorie diets and ACE in-
hibition drastically decrease the level of proteinuria in
patients with obesity-related proteinuria [46]. In addi-
tion, we have shown that weight loss induces a significant
proteinuria decrease in patients with chronic protein-
uric nephropathies of different causes (including diabetic
nephropathy and chronic glomerulonephritis), where pa-
tients who are considered overweight have a body mass
index >27 kg/m2. In this study, weight loss was moderate
(averaging 4.1% ± 3% at the end of the 5-month study),
but the effect on the level of proteinuria was striking:
a 31% ± 37% reduction in baseline values was found.
Furthermore, decrease in proteinuria and weight loss ex-
hibited a significant correlation: restricting the analysis to
those patients who lost more than 3% of baseline weight,
a proteinuria reduction of 50% ± 21% from baseline val-
ues was observed [47]. All these data indicate that weight
loss is a strong antiproteinuric measure, not only in pa-
tients with obesity-induced proteinuria, but also in over-
weight patients with any type of diabetic or nondiabetic
proteinuric renal disease. The fact that most patients with
type 2 diabetic nephropathy are obese reinforces the sig-
nificance of these observations.
Abdominal fat expresses higher levels of RAAS com-
ponents and is the main component of the metabolic syn-
drome; in turn, patients with metabolic syndrome are at
a high risk of developing albuminuria, proteinuria, and
chronic renal insufficiency [48]. Insulin resistance is a
crucial pathogenic event in the metabolic syndrome;
in this setting, clinical observation showing a signif-
icant reduction in microalbuminuria with peroxisome
proliferator-activated receptor c agonists, drugs that im-
prove sensitivity to insulin, are particularly interesting
[49].
FUTURE PERSPECTIVES
A milestone in the investigation of proteinuric renal
diseases has been the cloning and localization of several
proteins (nephrin, podocin, CD2AP, and others) that are
essential constituents of podocyte slit diaphragms [50].
Mutations in the genes coding for these proteins cause
different types of childhood nephrotic syndrome. More-
over, recent investigations have demonstrated that the
expression of these podocyte proteins is markedly re-
duced in any type of proteinuric renal disease, whatever
the cause [51]. Interestingly, blockade of RAAS with both
ACE inhibitors and ARA restores the expression of these
proteins, almost to normality, in experimental models of
proteinuria [52]. It is likely that the discovery of these
slit-diaphragm proteins will deepen our understanding of
the pathogenesis of proteinuric nephropathies and of the
mechanisms of many current antiproteinuric measures,
as well as inspire future therapeutic avenues.
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